Get started
Author

Marta Żołnowska

Observed names: M Zołnowska, Marta Zolnowska
Observed institution: University Clinical Centre
OpenAlex ID: A5019581113
Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial
2018 · Elizabeth A Thiele, Eric D Marsh, et al. · The Lancet · 945
Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex
2020 · Elizabeth A. Thiele, E. Martina Bebin, et al. · JAMA Neurology · 288
PDF
Long‐term cannabidiol treatment in patients with Dravet syndrome: An open‐label extension trial
2018 · Orrin Devinsky, Rima Nabbout, et al. · Epilepsia · 275
PDF
Add‐on cannabidiol in patients with Dravet syndrome: Results of a long‐term open‐label extension trial
2021 · Ingrid E. Scheffer, Jonathan J. Halford, et al. · Epilepsia · 96
PDF
A phase 2, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox–Gastaut syndrome ( ELEKTRA )
2022 · Cecil D. Hahn, Yuwu Jiang, et al. · Epilepsia · 81
PDF
Effects of an Extensively Hydrolyzed Formula Supplemented with Two Human Milk Oligosaccharides on Growth, Tolerability, Safety and Infection Risk in Infants with Cow’s Milk Protein Allergy: A Randomized, Multi-Center Trial
2022 · Yvan Vandenplas, Marta Żołnowska, et al. · Nutrients · 55
PDF
Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials
2021 · Jennifer Madan Cohen, Daniel Checketts, et al. · Epilepsia · 35
Efficacy, Safety and Tolerability of Soticlestat (TAK-935/OV935) as Adjunctive Therapy in Pediatric Patients with Dravet Syndrome and Lennox-Gastaut Syndrome (ELEKTRA) (4234)
2021 · Cecil D. Hahn, Yuwu Jiang, et al. · Neurology · 9
Soticlestat as an adjunctive therapy in children and young adults with Dravet syndrome
2026 · Joseph Sullivan, Kette Valente, et al. · Epilepsia · 7
Maintenance of Long-Term Safety and Efficacy of Cannabidiol (CBD) Treatment in Dravet Syndrome (DS): Results of the Open-Label Extension (OLE) Trial (GWPCARE5) (S19.003)
2018 · Ian Miller, Orrin Devinsky, et al. · Neurology · 6
Plasma proinsulin, C-peptide and sex hormone concentrations in regularly menstruating premenopausal females with ovulatory and anovulatory menstrual cycles.
2006 · G Lutoslawska, M Niedbalska, et al. · PubMed · 4
IP 110. Maintenance of Long-Term Safety and Efficacy of Cannabidiol Treatment in Dravet’s Syndrome: Results of an Open-Label Extension Trial (GWPCARE5)
2018 · Orrin Devinsky, Rima Nabbout, et al. · Neuropediatrics · 3
Prolonged fenfluramine use in open‐label studies of Dravet or Lennox–Gastaut syndromes: Long‐term safety, tolerability, patient global functioning, and considerations for interpreting effectiveness
2026 · Antonio Gil‐Nagel, Kelly G. Knupp, et al. · Epilepsia · 1
Long-Term Soticlestat Treatment in Patients with Developmental and/or Epileptic Encephalopathies in the ENDYMION Ongoing Open-Label Extension Study (4197)
2021 · Cecil D. Hahn, Yuwa Jiang, et al. · Neurology · 1
Is Lifelong Physical Activity a Determinant of Lung Transplantation Outcomes?
2026 · Natalia Muklewicz, Marta Gallas, et al. · Journal of Clinical Medicine
PDF
Works count: 15
Citation count: 1,806
H-index: 8
I10-index: 7
Year
Topic
Type